JeffreyLKaineMD

Rheumatology • Venice, FL

Physician

Join to view full profile

Dr. Kaine is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kaine's full profile

Already have an account?

Office
411 Commercial Ct
Ste C
Venice, FL 34292
Phone+1 941-484-4409

Fax+1 941-485-3444

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Rheumatology, 1983 - 1984
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1979 - 1983
Yale School of MedicineClass of 1979

Certifications & Licensure

NC State Medical License 2020 - 2025
FL State Medical License 1986 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

Sarasota Magazine: Top Doctors Castle Connolly, 2004-2006, 2009-2014
CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013
Top Doctors: Florida Castle Connolly, 2000
Fellow (FACR) American College of Rheumatology
Join now to see all

Clinical Trials

A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor Start of enrollment: 2013 Jul 01
Completed
Phase 2
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2012 Jun 01
Completed
Phase 2
A Study of LY3337641 in Rheumatoid Arthritis Start of enrollment: 2016 Aug 22
Terminated
Phase 2
A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis Start of enrollment: 2016 May 02
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis Start of enrollment: 2016 Apr 12
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis Start of enrollment: 2016 Aug 02
Completed
Phase 3
A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis Start of enrollment: 2017 May 09
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

205 citations
Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate
Stanley Cohen, Grant W. Cannon, Michael Schiff, Arthur L. Weaver, Robert I. Fox
Arthritis and Rheumatism. 2001-09-01
152 citations
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, d...
Mark C. Genovese, Jeffrey L. Kaine, Mitchell B. Lowenstein, Jose Del Giudice, Andrew R. Baldassare
Arthritis and Rheumatism. 2008-09-01
119 citations
The rapid assessment of disease activity in rheumatology (radar) questionnaire. Validity and sensitivity to change of a patient self-report measure of joint count and ...
John H. Mason, Jennifer J. Anderson, Robert F. Meenan, Kathleen M. Haralson, Donna Lewis-Stevens
Arthritis and Rheumatism. 1992-02-01

Press Mentions

The Negative Consequences of a Missed DiagnosisAugust 26th, 2019

Professional Memberships

American College of Rheumatology - ACR
Fellow